What Is Cancer Dormancy, and Why Does It Matter to Researchers?
Updated: Aug 20
Cancer can sometimes return years after treatment, even when tests have shown no detectable disease. One explanation researchers are studying is cancer dormancy—a state in which residual cancer cells survive without forming an actively growing, detectable tumor. Some may remain inactive for months, years, or possibly decades before conditions allow them to grow again.
Understanding this process could change how researchers approach cancer recurrence and metastasis. Instead of focusing only on destroying actively growing tumors, scientists are asking how residual cells survive, how the surrounding tissue controls them, and whether recurrence might someday be intercepted before a new tumor develops.
What Is Cancer Dormancy?
Cancer dormancy is an umbrella term for biological states in which cancer persists without producing an actively expanding, clinically detectable tumor. Researchers generally distinguish between dormancy of individual cells and dormancy of a microscopic tumor population.
Dormant cells can be part of minimal residual disease , meaning cancer cells remain after treatment even though conventional testing may not show an obvious tumor. However, minimal residual disease and dormancy are not identical concepts: residual cancer cells are not necessarily all dormant.
Cellular dormancy
In cellular dormancy, an individual cancer cell enters a reversible state called quiescence. It stops actively progressing through the cell cycle but remains alive and potentially capable of dividing again. This is different from a cell that has permanently lost the ability to reproduce.
Slow or non-dividing cells also present a treatment challenge. Many conventional chemotherapy drugs work best against cells that are actively dividing, so a quiescent population may respond differently from the rapidly growing tumor that was originally treated.
Tumor mass dormancy
A microscopic tumor population can also remain approximately stable even though some cells are dividing. In this situation, cell growth may be balanced by cell death, preventing the lesion from expanding into a detectable tumor.
Researchers describe angiogenic dormancy when limited formation of new blood vessels restricts expansion. Immune-mediated dormancy describes situations in which immune surveillance helps restrain tumor growth. These mechanisms can overlap rather than acting as completely separate categories.
How Does Cancer Dormancy Develop?
A cancer cell that leaves its original tumor faces a difficult journey. It must survive circulation, reach another tissue, adapt to an unfamiliar environment, and eventually establish a new tumor. Some disseminated tumor cells, or DTCs, may survive this process without immediately beginning sustained growth.
The tumor microenvironment
Dormancy is not controlled by cancer cells alone. Researchers increasingly study the tumor microenvironment—the surrounding immune cells, stromal cells, blood vessels, signaling molecules, and extracellular matrix that can influence whether a disseminated cell grows or remains quiet.
Signals from this local environment can activate stress-response pathways or alter gene activity inside cancer cells. The exact mechanisms differ among cancer types and metastatic organs, which is one reason researchers have not found a single universal “dormancy switch.”
Immune and blood-vessel control
Preclinical research suggests immune cells may actively hold certain disseminated cancer cells in dormancy. For example, NCI highlighted mouse studies in which lung macrophages and natural killer cells helped restrain disseminated breast cancer cells. These studies help identify mechanisms, but mouse results do not by themselves establish what will happen in individual patients.
Blood-vessel development can also influence whether a microscopic population remains restricted or begins expanding. Together, these observations support a broader view of dormancy as an interaction between the cancer cell and the biological environment around it.
Why Does Cancer Dormancy Matter for Recurrence and Metastasis?
Cancer recurrence can occur because malignant cells survived the original treatment. Dormancy offers one biological explanation for why some surviving cells may remain clinically silent for a long period before contributing to metastatic growth. It is not, however, proof that every late recurrence comes from a previously dormant cell.
Late recurrence is particularly well documented in some forms of breast cancer. Human studies of estrogen receptor-positive breast cancer have found that recurrence risk can persist for many years after initial treatment.
Researchers study dormancy as one possible mechanism behind this long clinical latency.
Evidence consistent with dormant cancer cells has also been reported in other solid tumors and some blood cancers. The NCI identifies metastatic dormancy as a major research area because understanding how cancer metastasis develops may reveal opportunities to prevent microscopic disease from becoming clinically significant metastasis.
How Do Researchers Study Cancer Dormancy?
Dormant cancer cells are difficult to investigate precisely because they are rare, quiet, and often located in tissues that are hard to sample. A conventional scan designed to locate a growing tumor may not reveal isolated disseminated cells.
Tracking residual cells
One approach is to look for disseminated tumor cells in tissues such as bone marrow. The 2025 CLEVER breast cancer study, for example, enrolled survivors who had detectable DTCs in bone marrow aspirates. Researchers could then study whether an intervention changed the number of detectable residual cells.
Circulating tumor DNA and other liquid-biopsy approaches are also being investigated as markers of molecular residual disease. However, finding residual tumor material is not the same as observing a particular living cell in a dormant state, so biomarkers need careful interpretation.
Building better models
Scientists use cell cultures, organ-like experimental systems, animal models, single-cell analysis, and other laboratory tools to study entry into dormancy and later reactivation. These approaches can reveal pathways involving metabolism, autophagy, immune escape, signaling, and the extracellular matrix.
The challenge is translation. A mechanism that produces dormancy in a laboratory system may not behave identically in a human tumor, and researchers need models that reproduce the long timelines and tissue-specific conditions seen in people.
What Can Wake Dormant Cancer Cells?
There is no single established answer to what causes dormant cancer cells to wake up. Researchers are investigating inflammatory signals, changes in immune surveillance, remodeling of surrounding tissue, new blood-vessel formation, metabolic conditions, and other changes in the local or systemic environment.
One notable 2025 Nature study found that influenza and SARS-CoV-2 infection could reactivate previously seeded dormant breast cancer cells in mouse lungs. The researchers also reported epidemiological associations between COVID-19 and metastatic outcomes in human datasets, but the human analyses cannot establish that an infection directly awakened dormant cells in an individual patient.
That distinction matters. Laboratory and animal studies can reveal mechanisms and generate hypotheses, while observational human data can identify associations. Neither should be converted into a personal prediction that a particular illness, inflammatory event, or lifestyle factor will cause a person's cancer to return.
Can Dormant Cancer Cells Be Targeted?
Dormancy creates an unusual therapeutic problem: scientists may need to target cells that are alive but behaving differently from rapidly dividing cancer. Several broad strategies are being investigated.
Table: Major research strategies for addressing dormant cancer cells
Research strategy | Basic idea | Current evidence | Important limitation |
Eliminate dormant cells | Exploit biological dependencies that keep dormant cells alive | Strong preclinical interest; early human research exists in selected settings | No universal dormant-cell target has been established |
Maintain dormancy | Keep residual cells from restarting sustained growth | Supported by biological models of immune and microenvironmental control | Long-term control and safety remain difficult to demonstrate |
Trigger and treat | Push cells out of quiescence so another therapy can attack them | Mostly experimental and context dependent | Reactivation could be harmful if treatment fails to eliminate the cells |
Modify the surrounding niche | Change immune, stromal, vascular, or extracellular-matrix signals | Extensive mechanistic research | Effects vary across organs, tumor types, and experimental models |
A particularly important step came from the randomized phase 2 CLEVER trial, published in Nature Medicine in 2025. Researchers studied 51 breast cancer survivors with detectable DTCs and tested hydroxychloroquine, everolimus, or their combination. The interventions reduced or cleared detectable DTCs in many participants, providing proof of concept that residual dormant-cell populations may be pharmacologically targetable.
The study does not establish these medicines as routine treatment for cancer dormancy. It was a small phase 2 study, and the authors concluded that a definitive randomized human trial is needed to determine whether targeting DTCs can reliably prevent recurrence.
Why Does Cancer Dormancy Matter to Researchers?
Cancer dormancy changes the research problem from treating visible disease to understanding invisible residual disease. Researchers want biomarkers that identify clinically meaningful dormant cells, models that predict their behavior, and interventions that stop microscopic disease from becoming metastasis.
Cancer dormancy shifts the question from “Did the tumor disappear?” to “What residual cells survived, what is keeping them quiet, and what could change that state?”
The NCI's metastatic dormancy research specifically focuses on the programs that maintain dormancy, signals that permit emergence, interactions with immune and stromal cells, and experimental models that may reveal therapeutic opportunities.
This work could eventually support a form of cancer interception: treating biologically important residual disease before a detectable metastatic tumor develops. That remains a research goal rather than an established approach across oncology, but the 2025 CLEVER results show why the question has moved closer to clinical investigation.
Safety and What This Research Means for Patients
Cancer dormancy research should not be used to change treatment or surveillance without an oncology team. There is currently no general test that can tell every cancer survivor whether dormant cells are present or whether they will reactivate, and investigational dormancy-targeting drugs should not be self-administered or substituted for established treatment.
After cancer treatment, cancer survivorship and follow-up care should be based on the cancer type, stage, previous treatment, symptoms, and appropriate clinical guidelines. Cancer.Net notes that recurrence monitoring and follow-up testing should be individualized rather than based on a single universal schedule.
New, persistent, or concerning symptoms should be discussed with the treating health care team rather than interpreted as evidence that dormant cells have “awakened.”
Conclusion
Cancer dormancy may help explain how residual cancer cells survive silently and, in some cases, contribute to recurrence or metastasis much later. Research now spans cell biology, immunology, the tumor microenvironment, biomarkers, animal models, and early clinical trials.
The major unanswered question is not simply whether dormant cells exist, but which cells matter clinically, what keeps them dormant, what triggers renewed growth, and whether researchers can intervene safely before metastatic disease appears. Current evidence makes cancer dormancy an important research frontier—not yet a universal clinical target.
Frequently Asked Questions
1. What does it mean when cancer is dormant?
Dormant cancer means residual cancer cells or a microscopic tumor population persist without producing ongoing, detectable tumor growth. Individual cells may enter reversible quiescence, while small populations can also remain stable through immune or blood-supply constraints. Dormancy does not mean the cancer will necessarily reactivate.
2. Can dormant cancer cells be detected?
Dormant cancer cells can sometimes be identified in research settings, but there is no universal clinical test for them. Investigators may study disseminated tumor cells in bone marrow or use molecular residual-disease approaches such as circulating tumor DNA. Detecting residual disease still does not reliably tell researchers which cells will later produce recurrence.
3. How long can cancer cells remain dormant?
Dormant cancer cells may persist for months, years, or potentially decades depending on the cancer and biological setting. Long intervals between initial treatment and recurrence are documented particularly well in some breast cancers. A long recurrence interval alone does not prove that a specific dormant cell caused the later disease.
4. What causes dormant cancer cells to wake up?
Researchers do not yet know one universal cause of dormant-cell reactivation. Immune changes, inflammation, tissue remodeling, vascular signals, and other microenvironmental factors are being investigated. Many proposed triggers come from laboratory or animal research and should not be treated as established causes of recurrence in individuals.
5. Can dormant cancer cells be treated?
Dormant cancer cells are being targeted experimentally, but there is no single established treatment for cancer dormancy across cancers. Researchers are testing approaches that eliminate dormant cells, keep them dormant, or alter the environment that supports them. The CLEVER study provides early human proof of concept in selected breast cancer survivors, but larger confirmatory trials are required.
6. Is cancer dormancy the same as remission?
No, cancer dormancy and remission describe different concepts. Remission is a clinical description of reduced or undetectable disease, while dormancy refers to the biology of residual cancer cells or microscopic tumor populations that are not actively expanding. A person can be in remission without researchers being able to determine whether dormant cells are present.
Comments